Page 1

H HARROW HEALTH INC . Harrow Health Announces Third Quarter 2021 Financial Results November 9 , 2021 Revenues Reach Record Levels for Fifth Consecutive Quarter Highlights for Third Quarter 2021 : • Record revenues of $ 18.7 million , a 30 % increase compared with $ 14.4 million for the prior - year period ; • Gross margin of 74 % consistent with prior - year period ; • Acquired AMP - 100 late - stage ophthalmic surgical drug candidate for FDA - approval ; Acquired MAQ - 100 ophthalmic surgical drug candidate for FDA - approval ; • Commissions from DEXYCUⓇ sales increased to $ 900,000 on record unit volumes ; and • Cash and cash equivalents was $ 57.9 million at September 30 , 2021 . NASHVILLE , Tenn .-- ( BUSINESS WIRE ) -- Nov . 9 , 2021-- Harrow Health , Inc. ( NASDAQ : HROW ) , an ophthalmic - focused healthcare company , today announced results for the third quarter and nine months ended September 30 , 2021. The Company also posted its third quarter Letter to Stockholders and corporate presentation to the " Investors " section of its website , harrowinc.com . This press release features multimedia . View the full release here : https://www.businesswire.com/news/home/20211109006451/en/ “ I am pleased to report a fifth consecutive quarter of strong top - line revenue growth for the third quarter of 2021 , a quarter which has historically been our slowest quarter of the year and one that continued to be affected by the COVID - 19 pandemic in certain regions of the country , " said Mark L. Baum , CEO of Harrow Health . " In addition to record revenue levels , we also reported record levels of other key financial and operational metrics such as revenue per shipping day and total number of product units dispensed . Gross margin for the third quarter of 2021 was consistent with the prior - year period and was down slightly from the sequential quarter primarily due to an investment in additional personnel to accommodate a second shift at our production facilities as we prepare to increase our capacity in 2022 . " During the third quarter , we also announced transactions to further our Strategic Vision and drive growth for many years to come , including the purchase of two drug candidates , AMP - 100 , an anesthetic drug candidate for intraoperative ocular pain management , and MAQ - 100 , an injectable steroid drug candidate for visualization of the vitreous during vitrectomy . " We have plowed the ground and begun making the investments necessary to transition Harrow into a company offering the compounded pharmaceuticals that our business was built upon as well as FDA - approved ophthalmic products . We are excited about the transformative potential of adding AMP - 100 and MAQ - 100 to our product portfolio , and we strongly believe that this is the type of ophthalmic pharmaceutical product offering that our customers want . " Conference Call and Webcast The Company's management team will host a conference call and live webcast today at 4:45 p.m. Eastern time to discuss the results and provide a business update . To participate in the call , see details below : Conference Call Details : Date : Tuesday , November 9 , 2021 Time : Participant Dial - in : Replay Dial - in ( Passcode 10160483 ) : ( telephonic replay through November 16 , 2021 ) 4:45 p.m. Eastern time 1-833-953-2434 ( U.S. ) 1-412-317-5763 ( International ) 1-877-344-7529 ( U.S. ) 1-412-317-0088 ( International )